Group One Trading, L.P. Argenx Se Transaction History

Group One Trading, L.P.

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 10, 2024	SELL	$356.95 - $413.29 $49,259 - $57,034	-138 Reduced 49.82%	139 $54,000
Q4 2023 Feb 14, 2024	SELL	$338.91 - $506.01 $112,179 - $167,489	-331 Reduced 54.44%	277 $105,000
Q3 2023 Nov 09, 2023	BUY	$369.35 - $548.43 $224,564 - $333,445	608 New	608 $298,000
Q1 2023 May 12, 2023	BUY	$334.23 - $403.65 $1.41 Million - $1.7 Million	4,218 New	4,218 $1.57 Million
Q2 2020 Aug 13, 2020	SELL	$127.44 - $232.72 $2.02 Million - $3.68 Million	-15,822 Closed	0 $0
Q1 2020 May 13, 2020	BUY	$108.83 - $165.23 $1.72 Million - $2.61 Million	15,822 New	15,822 $2.08 Million
Q4 2018 Feb 06, 2019	SELL	$63.81 - $109.82 $117,410 - $202,068	-1,840 Closed	0 $0
Q3 2018 Nov 08, 2018	BUY	$75.5 - $96.63 $138,920 - $177,799	1,840 New	1,840 $140,000

400

30.9M

376K

489K

Ticker ARGX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,323,800
Market Cap $34.8B
Description
argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, ...

Get notified when there are updates to the investment portfolio of Group One Trading, L.P., based on Form 13F filings with the SEC.

Stay updated on Group One Trading, L.P. with notifications on news.